References
- National Organization for Rare Disorders (NORD). Hepatocellular carcinoma (2017). https://rarediseases.org/rare-diseases/hepatocellular-carcinoma/
- BrayF, FerlayJ, SoerjomataramI, SiegelR, TorreL, JemalA. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394–424 (2004).
- American Cancer Society (ACS). Liver and intrahepatic bile duct (2020). https://cancerstatisticscenter.cancer.org/#!/cancer-site/Liver%20and%20intrahepatic%20bile%20duct
- YangJ, HainutP, GoresGet al. A global view of hepatocellular carcinoma: trends, risks, prevention and management. Nat. Rev. Gastroenterol. Hepatol. 16(10), 589–604 (2019).
- Surveillance, Epidemiology, and End Results (SEER). SEER cancer stat facts: liver and intrahepatic bile duct cancer. (2020). https://seer.cancer.gov/statfacts/html/livibd.html
- LlovetJM, KelleyRK, VillanuevaAet al. Hepatocellular carcinoma. Nat. Rev. Dis. Primers 7(1), 6 (2021).
- ReigM, FornerA, RimolaJet al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J. Hepatol. 76, 681–693 (2022).
- LurjeI, CziganyZ, BednarschJet al. Treatment strategies for hepatocellular carcinoma – a multidisciplinary approach. Int. J. Mol. Sci. 20(6), 1465 (2019).
- Nexavar prescribing information. Bayer HealthCare (2018). www.accessdata.fda.gov/drugsatfda_docs/label/2018/021923s020lbl.pdf
- LlovetJM, RicciS, MazzaferroVet al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 3359(4), 378–390 (2008).
- Abou-AlfaGK, MeyerT, ChengALet al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N. Engl. J. Med. 379, 54–63 (2018).
- BruixJ, QinS, MerlePet al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, Phase III trial. Lancet 389, 56–66 (2017).
- El-KhoueiryAB, SangroB, YauTet al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, Phase I/II dose escalation and expansion trial. Lancet 389(10088), 2492–2502 (2017).
- FinnRS, QinS, IkedaMet al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 382, 1894–1905 (2020).
- KudoM, FinnRS, QinSet al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised Phase III non-inferiority trial. Lancet 391, 1163–1173 (2018).
- YauT, KangYK, KimTYet al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial. JAMA Oncol. 6(11), e204564 (2020).
- ZhuAX, KangYK, YenCJet al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, Phase III trial. Lancet Oncol. 20(2), 282–296 (2019).
- ZhuAX, FinnRS, EdelineJet al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label Phase II trial. Lancet Oncol. 19(7), 940–952 (2018).
- Henry Ford Health Systems. 2019 Fact Sheet (2019). www.henryford.com/newsroom/facts
- ParkJW, ChenM, ColomboMet al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study. Liver Int. 35, 2155–2166 (2015).
- TsorisA, MarlarCA. Use of the Child Pugh score in liver disease (2022). www.ncbi.nlm.nih.gov/books/NBK542308/
- AichesonG, PillaiA, DahmanB, JohnBV. Recent advances in systemic therapies for advanced hepatocellular carcinoma. Curr. Hepatol. Rep. 20, 23–33 (2021).
- GordanJD, KennedyEB, Abou-AlfaGKet al. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline. J. Clin. Oncol. 38, 4317–4345 (2020).